Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

Nov 15, 2021

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Nov. 15, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in November. Details are as follows:

Northland Synthetic Lethality Investor Conference
Date: Wednesday, November 17, 2021
Time: 9:30 a.m. Eastern Time

Piper Sandler Healthcare Conference
Date: Monday, November 29Thursday, December 2, 2021

A live webcast of the Northland Synthetic Lethality Investor Conference panel discussions will be available starting Wednesday, November 17, 2021 at 9:30 a.m. Eastern Time in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for 90 days.

The prerecorded Piper Sandler Healthcare Conference fireside chat will be available on Monday, November 22, 2021 at 10 a.m. Eastern Time in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for 90 days.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as eight other early-stage, pre-clinical programs. For more information, please visit reparerx.com.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

Repare:

Steve Forte
Chief Financial Officer
Repare Therapeutics Inc.
info@reparerx.com

Investors:

Kimberly Minarovich
Argot Partners
repare@argotpartners.com

Media:

David Rosen
Argot Partners
david.rosen@argotpartners.com
212-600-1902

Source: Repare Therapeutics Inc.